英文名 :IL-38 (aa 3-152) (mouse) (rec.) (FLAG)
保存条件 :-20°C
库存 :99
供应商 :欣博盛生物
规格 :10 ug
IL-38 (aa 3-152) (mouse) (rec.) (FLAG)产品由Adipogen公司生产,产地是瑞士。该产品货号为AG-40B-0101-C010,包装规格是10 ug。如需购买该产品,询问折扣价/货期/技术问题,请联系Adipogen授权代理商——欣博盛生物
品牌:Adipogen
货号:AG-40B-0101-C010
品名:IL-38 (aa 3-152) (mouse) (rec.) (FLAG)
产品信息:
产品类型:蛋白
来源:E.coil。
种属反应:Mouse
分子量:20kDa左右
纯度:≥95% (SDS-PAGE)
浓度:重组后1mg/ml
重组:100μl无菌水。
成分:冻干。含PBS + 0.5%海藻糖+ 0.02% CHAPS。
产品介绍:
IL-38 (IL-1F10) mRNA表达于心脏、胎盘、胎肝、脾脏、胸腺和扁桃体。 IL-1F10在多种免疫组织中的表达及与IL-1Ra的相似性表明IL-1F10在炎症反应中发挥作用。 据报道,去除IL-1F家族的白细胞介素,如IL-1F5 / 6 / 8或9(也称为IL-36Ra、IL-36α、IL-36β或IL-36γ)的n端结构域对提高其生物活性非常重要。最近的研究表明IL-38是由凋亡细胞n端加工和分泌的。释放的经过处理的IL-38(20-152)与受体白介素-1受体附属蛋白样1 (IL1RAPL1; TIGIRR-2)在巨噬细胞表面。经过处理的IL -38激活的IL1RAPL1减少了IL-6的产生,导致炎症减弱。
欣博盛生物为Adipogen中国授权代理商,如需购买产品,请联系欣博盛生物。
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029
上海: 021-34613729 广州: 020-87615159
代理品牌网站: www.neobioscience.com
自主品牌网站: www.neobioscience.net
该产品被引用文献
- In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice: M. Chu, et al.; Immunobiology 222, 483 (2017)
- The effect of interleukin 38 on angiogenesis in a model of oxygen-induced retinopathy: J. Zhang, et al.; Sci. Rep. 7, 2756 (2017)
- The enigmatic role of IL-38 in inflammatory diseases: T. Garraud, et al.; Cytokine Growth Factor Rev. 39, 26 (2018)
- Interleukin 38 protects against lethal sepsis: F. Xu, et al.; J. Infect. Dis. 218, 1175 (2018)
- The Effect of Interleukin 38 on Inflammation-induced Corneal Neovascularization: J. Zhu, et al.; Curr. Mol. Med. 19, 589 (2018)
- Interleukin‐38 alleviates cardiac remodelling after myocardial infarction: Y. Wei, et al.; J. Cell. Mol. Med. 24, 371 (2020)
- IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis: W.D. Xu, et al.; J. Cell Mol. Med. 24,12379 (2020)
- IL-38 Alleviates Inflammation in Sepsis in Mice by Inhibiting Macrophage Apoptosis and Activation of the NLRP3 Inflammasome: Y. Ge, et al.; Mediat. Inflamm. 6370911 (2021)
- Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity: H. Li, et al.; Invest. Ophthalmol. Vis. Sci. 62, (2021)
- Multifaceted roles of IL-38 in inflammation and cancer: A. Diaz-Barreiro, et al.; Cytokine 151, 155808 (2022)
- IL-38, a potential therapeutic agent for lupus, inhibits lupus progression: WD. Xu, et al.; Inflamm. Res. 71, 963 (2022)
- Regulatory effect of IL-38 on NF-κB pathway in systemic lupus erythematosus: J. Zhang, et al.; Immunobiol. ahead of print (2022)